Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Ajinomoto Co., Inc. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a prospective, multi-center study to evaluate the diagnostic performance characteristics of the AminoIndexâ„¢ technology among patients at high risk for developing lung cancer as compared with standard lung cancer screening and diagnostic procedures including low-dose CT, high-dose CT, biopsy and histopathology.
This is a prospective, multi-center study to evaluate the diagnostic performance characteristics of the AminoIndexâ„¢ technology among patients at high risk for developing lung cancer as compared with standard lung cancer screening and diagnostic procedures including low-dose CT, high-dose CT, biopsy and histopathology.
The study will enroll patients into one of three arms:
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group 1 | Patients with lung nodule(s) ≥ 6 mm but ≤ 35 mm that have been biopsied and diagnosed with primary lung cancer who have not yet initiated treatment of any kind for their lung cancer will contribute a fasting blood sample. | ||
| Group 2 | Patients whose most recent screening imaging is within 60 days who have lung nodule(s) ≥ 6 mm but ≤ 35 mm that have been biopsied and determined to not be cancerous OR that have demonstrated no nodule growth for >2 years by repeat CT imaging will contribute a fasting blood sample. | ||
| Group 3 | Patients who have undergone low-dose computed tomography (LDCT) or standard computed tomography (CT) or X-ray testing to screen for lung cancer with no nodules suspicious for lung cancer within 1 year prior to signing informed consent will contribute a fasting blood sample. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| The diagnostic performance of AminoIndexâ„¢ to discriminate lung cancer patients from high-risk subjects. | To evaluate the diagnostic performance characteristics of the AminoIndexâ„¢ technology among patients at high risk for developing lung cancer as compared with standard lung cancer screening and diagnostic procedures including low-dose CT, high-dose CT, biopsy and histopathology. | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| The capability of AminoIndexâ„¢ to distinguish malignant lung cancer from benign lung nodules. | 6 months | |
| Gathering residual patient samples that will be used for discovery research. | 6 months |
Not provided
Inclusion Criteria
All Groups:
Group 1:
Group 2:
Men or women age 18 years or older;
Lung nodule size ≥ 6 mm but ≤ 35 mm/ lung nodule, lesion or mass;
Definitive diagnosis of benign (non-cancerous) lung nodule based upon one of the following:
Group 3:
' * ' One pack year is calculated as follows: 20 cigarettes = 1 pack. One "pack year" is the equivalent of smoking:
Exclusion Criteria
Not provided
Not provided
Study will enroll sufficient subjects to yield a minimum of 60 subjects in Study Group 1, 30 subjects in Study Group 2 and 60 subjects in Study Group 3 - a total of 150 evaluable study subjects who meet all inclusion and exclusion criteria. Eligible subjects will be men and women age ≥ 18 years for Group 1 and 2 and 55 - 79 years inclusive for Group 3. Group 3 study subjects must also meet NLST guidelines of being at high risk for lung cancer: greater than or equal to a 30 pack year smoking history (equivalent of 1 pack per day for 30 or more years) and a current smoker or quit less than 15 years ago.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Gregg S. Britt | Innovis LLC | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Florida Lung Asthma and Sleep Specialists P.A. | Celebration | Florida | 34747 | United States | ||
| Pulmonary and Critical Care Associates of Baltimore |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D008175 | Lung Neoplasms |
| ID | Term |
|---|---|
| D012142 | Respiratory Tract Neoplasms |
| D013899 | Thoracic Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Subjects will consent to archiving and future analysis of their blood samples for up to twenty (20) years.
| Baltimore |
| Maryland |
| 21237 |
| United States |
| Vanderbilt-Ingram Cancer Center (VICC) | Nashville | Tennessee | 37232 | United States |
| D008171 |
| Lung Diseases |
| D012140 | Respiratory Tract Diseases |